CORDStrom Pivotal Trial Completed, UK Filing Set for H2 2026
INMB sits 86% above its 52-week low of $1.09.
Summary
INmune Bio completed the pivotal CORDStrom trial and will file for UK conditional marketing authorization in Q3–Q4 2026, with an EU filing in early 2027 and a BLA to follow. This is the first confirmation the trial is done and the regulatory path is locked in. Q2 financials show a $1.3M net loss and $18.4M in cash, funding operations into Q2 2027 at a monthly burn of $1.0–$1.5M. The timeline follows positive MHRA alignment in June and puts the company on track for a potential approval in 2027.
At the time of this announcement, INMB was trading at $2.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $57.9M. The 52-week trading range was $1.09 to $2.85. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.